Back to Homepage
Health

Cannabis Extract Relieves Chronic Back Pain -Trial

Aglow News
September 30, 2025
Cannabis Extract Relieves Chronic Back Pain -Trial

Cannabis Extract Relieves Chronic Back Pain -Trial

Lower back pain is the leading cause of disability worldwide, affecting more than half a billion people, according to the World Health Organization. A specially developed cannabis extract relieves chronic lower back pain, according to a clinical trial published Wednesday that experts are calling the first high-quality evidence that something in the cannabis plant can treat pain.

Lower back pain is the leading cause of disability worldwide, affecting more than half a billion people, according to the World Health Organisation.But drugs for chronic back pain are limited to common painkillers such as ibuprofen, which can have serious side effects when used long-term, or highly addictive and potentially dangerous opioids.

In recent years, an expanding cannabis industry has claimed that a range of marijuana or cannabidiol (CBD) products can help with pain, but researchers have warned that the quality of evidence actually showing this has been low.On Wednesday, a large placebo-controlled, phase 3 clinical trial which is considered the gold standard for researching medical drugs testing a cannabis extract was published in the journal Nature Medicine.

Article image

The trial involved more than 800 people with chronic lower back pain who did not get relief from non-opioid drugs. After 12 weeks of taking either the cannabis extract called VER-01 or a placebo, participants were asked to report their pain level on a 10-point scale. Those taking the extract reported a 1.9-point reduction in pain, compared to 0.6 for those on the placebo.After six months, participants taking the extract said their pain had decreased by a higher 2.9 points.

They also reported better sleep, physical function and quality of life, according to the study.Each dose of VER-01 contains 2.5 milligrammes of THC, the main active ingredient in marijuana.Nothing suggested that the extract was addictive or caused serious side effects, the study said. The most common side effects were short-term dizziness, sleepiness, dry mouth and some nausea though they decreased over time.

The study’s lead author, Matthias Karst, a professor of pain medicine at Hannover Medical School in Germany, told AFP that “no feelings of (being) high” were observed during the trial.‘As Good As It Gets’Andrew Moore, a former pain researcher at Oxford University not involved in the study, said the “terrific” trial was “about as good as it gets”.

“The trial is the first that shows good quality evidence that something in the cannabis plant can be helpful for pain,” he told AFP.But Moore also urged caution about claims that the extract was not addictive, warning that in the past, such statements have later turned out to be incorrect.Most cannabis products vary widely in potency, purity and other factors which make them difficult for doctors to safely prescribe, Karst said.The VER-01 strain has been specifically developed to obtain approval by medical authorities and then be prescribed for chronic pain, he added.

This means the study is not “proof that all cannabis/CBD products would be helpful in the same way,” Karst emphasised.Jan Vollert, a pain researcher at Exeter University not involved in the study, also stressed the difference between this “very specific substance” and regular marijuana.“Smoking cannabis and taking VER-01 are probably as similar as eating hazelnuts and eating Nutella: they might share a similar basis, but they just are not comparable,” he said.

Tags

Health

Related Posts

Health: US To Zero Out Tariffs On UK Pharma Under Trade Deal

Health: US To Zero Out Tariffs On UK Pharma Under Trade Deal

The United States has agreed to eliminate tariffs on British pharmaceutical imports under a new deal requiring the UK to increase spending on American-made drugs by 25 percent. The agreement, announced Monday, aims to correct what US officials describe as long-standing trade imbalances and ensure fairer pricing for American treatments. In exchange for tariff relief, the UK’s NHS will pay higher prices for new US therapies, becoming the only country granted exemption from the steep tariffs introduced on October 1. The move comes amid broader US scrutiny of global drug-pricing practices and follows major investment commitments in US manufacturing by firms such as AstraZeneca and Pfizer.

NTS Urges FG To Prioritise Health Funding, Modernise Hospitals

NTS Urges FG To Prioritise Health Funding, Modernise Hospitals

The Nigerian Thoracic Society (NTS) has urged the Federal Government to prioritise increased health funding and modernise hospital infrastructure to address Nigeria’s rising burden of respiratory diseases. In a communiqué issued after its 32nd Annual General Meeting in Lagos, the society called for fully equipped regional centres of excellence, stronger documentation practices, and wider public education on tobacco risks and emergency response. Delegates also examined how technology and AI can enhance respiratory care, stressing that while AI offers major benefits, it cannot replace healthcare professionals.

Cervical Cancer Vaccine Push Has Saved 1.4 Million Lives — Gavi

Cervical Cancer Vaccine Push Has Saved 1.4 Million Lives — Gavi

Gavi, the Vaccine Alliance, says its three-year campaign to expand access to HPV vaccines in low-income countries has prevented an estimated 1.4 million future cervical cancer deaths. The organisation reports that 86 million girls are now protected against HPV—the leading cause of cervical cancer—which disproportionately affects poorer nations lacking screening and treatment services. HPV-related cervical cancer caused 350,000 deaths in 2022, with 90% occurring in low-income countries. Gavi added that vaccine coverage in Africa has risen from 4% in 2014 to 44% in 2024, supported by reduced vaccine prices and increased manufacturer commitments.

Share this article